Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
12/29/2025 08:00 AM • Reviva Pharmaceuticals Holdings, Inc. announced that its Founder, President, and CEO Laxminarayan Bhat will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. The late-stage biopharmaceutical company is developing therapies for CNS, inflammatory, and cardiometabolic diseases, with two main drug candidates: brilaroxazine (RP5063) and RP1208.
RVPH - The article is primarily a conference presentation announcement with standard corporate disclosure. While the company mentions ongoing FDA interactions and potential NDA submission timelines for brilaroxazine, the main content is promotional in nature. The regulatory update referenced suggests FDA requested additional Phase 3 data, which is neither particularly positive nor negative, representing a typical development pathway adjustment.